Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACUVAIL vs ANOQUAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.
Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.
Reduction of ocular pain and inflammation following cataract surgery,Treatment of ocular itching associated with seasonal allergic conjunctivitis
Hypertension
1 drop in the affected eye 4 times daily.
100 mg orally twice daily
Terminal elimination half-life is approximately 46 minutes in the aqueous humor following ocular administration in humans.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via conjugation with glucuronic acid; minor role of cytochrome P450 enzymes. Approximately 50% is excreted as parent drug and metabolites in urine.
Hepatic metabolism via oxidation and conjugation; metabolites excreted renally.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for <10%.
Renal excretion accounts for approximately 70% of the dose (50% as unchanged drug, 20% as inactive metabolites); biliary/fecal excretion accounts for 30%.
>99% bound to plasma proteins, primarily albumin.
Approximately 90% bound to albumin.
Intravenous administration in animals suggests Vd ~0.15 L/kg, indicating limited distribution; clinically, it distributes into aqueous humor after topical dosing.
0.8-1.2 L/kg, indicating extensive distribution into total body water.
Ocular bioavailability is dependent on formulation; systemic bioavailability after topical ocular administration is extremely low (<1%).
Oral: 60-70% due to first-pass metabolism.
No adjustment required. Drug is minimally systemically absorbed.
GFR 30-50 m L/min: 100 mg once daily; GFR <30 m L/min: 50 mg once daily; not recommended for GFR <15 m L/min
No adjustment required. Drug is minimally systemically absorbed.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: not recommended
Safety and efficacy in pediatric patients have not been established.
Not approved for pediatric use; no established dosing
No specific dosage adjustment is recommended; use same dose as younger adults.
No specific adjustment; monitor renal function and consider reduced initial dose (50 mg twice daily) in patients >65 years with renal impairment
No black box warning for ophthalmic use; however, systemic NSAIDs carry risk of serious cardiovascular and gastrointestinal events. Ophthalmic use rarely associated with corneal adverse events.
No FDA black box warning.
Use with caution in patients with bleeding disorders or those on anticoagulants; may prolong bleeding time. Avoid in patients with known hypersensitivities to NSAIDs or aspirin. Can cause corneal keratopathy; discontinue if corneal epithelial breakdown occurs.
Rebound hypertension upon abrupt discontinuation; sedation and drowsiness; potential for orthostatic hypotension; caution in patients with severe coronary insufficiency or cerebrovascular disease.
Hypersensitivity to any component of the formulation. Active corneal epithelial defect. Patients with aspirin-sensitive asthma.
Known hypersensitivity to guanabenz; patients with severe hepatic or renal impairment.
No specific food interactions; systemic absorption is minimal with ophthalmic use. Avoid concurrent use of other NSAID eye drops due to additive irritation.
Avoid grapefruit and grapefruit juice as they may increase quinine levels. Take with a full glass of water. May be taken with meals to reduce nausea.
Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester. Use during the first and second trimesters should be limited to cases where potential benefit outweighs risk; avoid during the third trimester due to risk of fetal harm.
Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and third trimester exposure is associated with fetal nephrotoxicity, oligohydramnios, and premature closure of the ductus arteriosus.
Ketorolac is excreted in human milk following systemic administration, but ocular doses produce negligible systemic levels. The M/P ratio is not determined for ophthalmic use. Use with caution in nursing mothers, as the clinical significance is likely low due to minimal systemic absorption.
Excreted in human milk. M/P ratio not determined. Avoid breastfeeding due to potential for serious adverse reactions in the nursing infant, including renal impairment and electrolyte disturbances.
No dosage adjustment is required for ophthalmic use during pregnancy, as systemic exposure is negligible. However, avoid use in third trimester due to risks. Pharmacokinetic changes in pregnancy do not significantly alter ocular delivery.
Anoquan is contraindicated in pregnancy; no dose adjustments are recommended because use during pregnancy is not advised.
Acuvail (ketorolac tromethamine ophthalmic solution 0.45%) is a nonsteroidal anti-inflammatory drug (NSAID) for ocular use. It is preserved with sodium chloride and not benzalkonium chloride, reducing corneal epithelial toxicity. Administer 1 drop twice daily for ocular pain and inflammation following cataract surgery. Use caution in patients with bleeding tendencies or those on anticoagulants due to risk of increased ocular bleeding. Monitor for corneal epithelial defects and keratitis, especially with prolonged use.
ANOQUAN (quinine sulfate) is used for uncomplicated Plasmodium falciparum malaria. Monitor for cinchonism (tinnitus, headache, nausea). Avoid in G6PD deficiency due to hemolysis risk. Correct hypoglycemia frequently. Use with caution in atrial fibrillation due to QT prolongation.
Wash hands before each use; do not touch tip of bottle to eye or any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Contact your doctor if you experience eye pain, redness, vision changes, or if symptoms worsen.,Do not use this medication while wearing contact lenses unless directed by your doctor.,Store at room temperature, keep bottle tightly closed when not in use, and discard within 28 days of opening.
Take with food to reduce gastrointestinal upset.,Complete full course even if symptoms improve.,Report ringing in ears, confusion, or vision changes.,Avoid driving if dizziness or visual disturbances occur.,Inform doctor of any history of G6PD deficiency or cardiac arrhythmias.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACUVAIL vs ANOQUAN, answered by our medical review team.
ACUVAIL is a NSAID Ophthalmic that works by Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.. ANOQUAN is a Local Anesthetic that works by Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACUVAIL and ANOQUAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACUVAIL is: 1 drop in the affected eye 4 times daily.. The standard adult dose of ANOQUAN is: 100 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACUVAIL and ANOQUAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACUVAIL is classified as Category C. Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause . ANOQUAN is classified as Category C. Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.